Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn about a recent article by Faizan Mazhar et al, adding:
“Inflammation vs cholesterol: which residual risk matters most in ASCVD?
A large real-world study explored how cholesterol risk (LDL-C) and inflammatory risk (hsCRP) relate to cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD).
Researchers analyzed 39,638 patients with ASCVD in routine healthcare in Stockholm between 2007–2021. Patients were stratified into four groups based on LDL-C greater than or equal to 1.8 mmol/L (approximately 70 mg/dL) and hsCRP greater than or equal to 2 mg/L:
- Low risk
- High cholesterol risk
- High inflammatory risk
- Combined high cholesterol plus inflammatory risk
The primary endpoint was major adverse cardiovascular events (MACE), with additional outcomes including cardiovascular mortality, all-cause mortality, and heart failure hospitalization.
Key findings
Inflammatory risk mattered more than cholesterol alone!!!
Patients with high inflammatory risk (hsCRP greater than or equal to 2 mg/L) had significantly higher rates of:
- MACE
- cardiovascular mortality
- all-cause mortality
- heart failure hospitalization
High cholesterol alone was associated with only a modest increase in MACE and was not strongly linked to other adverse outcomes.
Another striking observation: approximately 39% of ASCVD patients were not receiving lipid-lowering therapy, highlighting persistent gaps in secondary prevention in routine care.
Why this matters
The study reinforces a growing concept in cardiometabolic medicine:
Residual inflammatory risk remains a major driver of cardiovascular events even when cholesterol is treated.
This helps explain why therapies targeting inflammation (e.g., colchicine, IL-1 pathways) are increasingly explored alongside lipid-lowering strategies.
Take-home message
ASCVD risk is not just about LDL-C.
In real-world populations, inflammation appears to be an equally important — and often overlooked — driver of recurrent cardiovascular events.
Future prevention strategies will likely need to target both cholesterol and inflammation. ”
Title: Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care
Authors: Faizan Mazhar, Davide Capodanno, Paul Hjemdahl, Arvid Sjölander, Sofia Gerward, Jimmi Mathisen, Oscar Plunde, Vijay Kunadian, Tomas Jernberg, Juan-Jesus Carrero
Read the Full Article on European Heart Journal Open
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
-
Apr 22, 2026, 07:19Sarah Richardson: Bringing Insights from HFA Symposium Back to Real Life
-
Apr 22, 2026, 07:17Karuna Kumar: Interesting Trial from Gambia on Treating Iron Deficiency in Children
-
Apr 22, 2026, 07:12Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America